Literature DB >> 8782464

Microsatellite alterations in serum DNA of head and neck cancer patients.

H Nawroz1, W Koch, P Anker, M Stroun, D Sidransky.   

Abstract

Microsatellite DNA alterations are an integral part of neoplastic progression and are valuable as clonal markers for the detection of human cancers. Moreover, recent evidence suggests that senescent tumor cells may release DNA into the circulation, which is subsequently carried by and therefore enriched in the serum and plasma. We tested 21 patients with primary head and neck squamous cell carcinoma (HNSCC) by polymerase chain reaction (PCR)-based microsatellite analysis of DNA from lymphocytes and paired serum samples. Patients were scored for alterations as defined by the presence of new alleles (shifts) or loss of heterozygosity (LOH) in serum at each of 12 markers and then compared with primary tumor DNA. Six out of 21 patients (29%) were found to have one or more microsatellite alterations in serum precisely matching those in the primary tumors. All six patients had advanced disease (stage III or IV); five of these patients had nodal metastases, three later developed distant metastases, and four died of disease. Microsatellite analysis of serum represents a novel method for the detection of circulating tumor cell DNA. If these results are confirmed in larger studies, microsatellite markers may be useful in assessing tumor burden in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782464     DOI: 10.1038/nm0996-1035

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  109 in total

1.  Digital PCR.

Authors:  B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Selective 'stencil'-aided pre-PCR cleavage of wild-type sequences as a novel approach to detection of mutant K-RAS.

Authors:  A V Lichtenstein; O I Serdjuk; T I Sukhova; H S Melkonyan; S R Umansky
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

3.  Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability.

Authors:  Kathryn Farrand; Lydija Jovanovic; Brett Delahunt; Bryan McIver; Ian D Hay; Norman L Eberhardt; Stefan K G Grebe
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

Review 4.  The detection of circulating breast cancer cells in blood.

Authors:  A M Gilbey; D Burnett; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

5.  Restriction endonuclease-catalyzed cleavage of DNA stimulates subsequent polymerase chain reaction and enables discrimination between normal and mutant K-RAS alleles.

Authors:  I V Botezatu; O I Serdyuk; G I Potapova; V P Shelepov; A V Likhtenshtein
Journal:  Dokl Biochem Biophys       Date:  2003 Nov-Dec       Impact factor: 0.788

6.  Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.

Authors:  David J McBride; Arto K Orpana; Christos Sotiriou; Heikki Joensuu; Philip J Stephens; Laura J Mudie; Eija Hämäläinen; Lucy A Stebbings; Leif C Andersson; Adrienne M Flanagan; Virginie Durbecq; Michail Ignatiadis; Olli Kallioniemi; Caroline A Heckman; Kari Alitalo; Henrik Edgren; P Andrew Futreal; Michael R Stratton; Peter J Campbell
Journal:  Genes Chromosomes Cancer       Date:  2010-11       Impact factor: 5.006

Review 7.  Tumor heterogeneity in the clinic: is it a real problem?

Authors:  Filip Janku
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

Review 8.  Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.

Authors:  Aadel A Chaudhuri; Michael S Binkley; Evan C Osmundson; Ash A Alizadeh; Maximilian Diehn
Journal:  Semin Radiat Oncol       Date:  2015-05-15       Impact factor: 5.934

9.  Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC.

Authors:  Mingchuan Zhao; Yishi Zhang; Jiayu Li; Xuefei Li; Ningning Cheng; Qi Wang; Weijing Cai; Chao Zhao; Yayi He; Jianhua Chang; Caicun Zhou
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

10.  Mutations of p53 gene can be detected in the plasma of patients with large bowel carcinoma.

Authors:  F Mayall; G Jacobson; R Wilkins; B Chang
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.